Endovasc’s licenses and patents describe technological advancements related to liposomes, stent coatings, and biodegradable/resorbable prostheses (stents) for the treatment of vascular dysfunction and heart disease. It also holds licenses and patents for the treatment of vascular dysfunction related to heart disease.

Stem Cell Innovations is a publicly-traded (SCLL.OB) cell biology company. The company is well positioned to become a leader in the development of next generation drug discovery solutions including human cellular disease models and cell-based therapies. SCI's proprietary stem cell platform named PluriCells (TM) is capable of generating a broad range of differentiated human cell types.

HemaCare collects, processes and distributes human blood products to hospitals and research-related organizations. We operate donor centers and mobile donor vehicles to collect transfusable blood products from donors, and offer human-derived blood products to health research organizations. HemaCare also provides blood related services, principally therapeutic apheresis procedures, stem cell collection and other blood treatments, to patients and in connection with clinical trials.

BrainStorm (OTC BB: BCLI) is a company that is developing stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing adult stem cells taken from the patient's own bone marrow to treat diseases such as Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease), and Spinal Cord Injury.